ライフサイエンスコーパス: overdiagnosis

1 rcinoma-related cancers (histology shift and overdiagnosis).

2 d avenues for incidental findings and cancer overdiagnosis.

3 ed to optimize these and to further quantify overdiagnosis.

4 s well as possible ways to avoid unnecessary overdiagnosis.

5 tially increase screening success and reduce overdiagnosis.

6 troversial because of adverse events such as overdiagnosis.

7 ess incidence under screening as a proxy for overdiagnosis.

8 false-positive rates, and the potential for overdiagnosis.

9 hy screening entails a substantial amount of overdiagnosis.

10 munologic assays for HIT results in frequent overdiagnosis.

11 l-described biases of lead time, length, and overdiagnosis.

12 idioides) difficile infection (CDI) leads to overdiagnosis.

13 extent to which the data are consistent with overdiagnosis.

14 en (10 to 14 months) in an attempt to reduce overdiagnosis.

15 hat screening is associated with substantial overdiagnosis.

16 ionizing radiation exposure, and the risk of overdiagnosis.

17 aviours may be important determinants of CMA overdiagnosis.

18 onfirmed TB but had low specificity, risking overdiagnosis.

19 ents with ANOCA but may increase the risk of overdiagnosis.

20 tion of thin melanoma, raising concern about overdiagnosis.

21 rostate cancer is burdened by a high rate of overdiagnosis.

22 g can lead to problems of underdiagnosis and overdiagnosis.

23 s, false-positive radiological findings, and overdiagnosis.

24 er death, side effects, false positives, and overdiagnosis.

25 n the United States has been suggested to be overdiagnosis.

26 en outcomes are favorable and this may avoid overdiagnosis.

27 ocioeconomic status were associated with CMA overdiagnosis.

28 ased radiation exposure, and a potential for overdiagnosis.

29 e breasts but does not estimate the level of overdiagnosis.

30 of atypia that are more likely to represent overdiagnosis.

31 chanisms and the epidemiologic phenomenon of overdiagnosis.

32 s diagnosed earlier in the LDCT arm suggests overdiagnosis.

33 eening studies directly examined the risk of overdiagnosis.

34 Concerns have been expressed about asthma overdiagnosis.

35 nomic disease while avoiding the pitfalls of overdiagnosis.

36 ings and compared excess incidence with true overdiagnosis.

37 MRI in women with breast cancer may lead to overdiagnosis.

38 sitive results and, possibly, an increase in overdiagnosis.

39 he importance of ductal carcinoma in situ in overdiagnosis.

40 e figures suggest at worst a small amount of overdiagnosis.

41 ng the potential harms, including those from overdiagnosis.

42 risks for prostate cancer death (2.27%) and overdiagnosis (2.4%), but reduces total tests by 59% and

43 imbalance suggests that there is substantial overdiagnosis, accounting for nearly a third of all newl

44 ulation subgroups; trends most suggestive of overdiagnosis alone were present in females aged 55-74.

45 ecome clinically apparent without screening (overdiagnosis), although there is uncertainty about this

46 posed FLC reference values would reduce MGUS overdiagnosis among Black individuals, avoiding unnecess

47 Overdiagnosis, an important harm of screening, is of unc

48 pathway for prostate cancer has resulted in overdiagnosis and consequent overtreatment as well as un

49 However, improved detection has also led to overdiagnosis and consequently overtreatment of patients

50 possible associations between perceptions of overdiagnosis and diagnostic practices have been studied

51 does not account for the high rate of sepsis overdiagnosis and encourages aggressive antibiotics for

52 linical trial population to characterise CMA overdiagnosis and identify individual-level and primary

53 men at higher risk could potentially reduce overdiagnosis and improve the benefit-harm tradeoff and

54 more or less health care and knowledge about overdiagnosis and informed choice among men in Australia

55 Associations between perceptions regarding overdiagnosis and interpretive behavior on study cases.

56 iations were found between perceptions about overdiagnosis and interpretive behavior when diagnosing

57 ers diagnosed, while minimizing the harms of overdiagnosis and maintaining cost-effectiveness.

58 ng, including the impact on quality of life, overdiagnosis and over-treatment.

59 arms of treatment and indirect evidence that overdiagnosis and overtreatment are likely to be substan

60 thyroid cancer is rising steadily because of overdiagnosis and overtreatment conferred by widespread

61 This review found evidence of ADHD overdiagnosis and overtreatment in children and adolesce

62 This strategy could help to avoid overdiagnosis and overtreatment in patients with Barrett

63 The adverse effects of overdiagnosis and overtreatment observed in men with cli

64 r remains controversial because it increases overdiagnosis and overtreatment of clinically insignific

65 Recent recognition of the overdiagnosis and overtreatment of ductal carcinoma in s

66 Overdiagnosis and overtreatment of indolent prostate can

67 Overdiagnosis and overtreatment of LB is worsening.

68 Overdiagnosis and overtreatment of Lyme disease are asso

69 The adverse consequences associated with overdiagnosis and overtreatment of Lyme disease, althoug

70 duce adenoma miss rates, but it may increase overdiagnosis and overtreatment of nonneoplastic polyps.

71 This is causing a high degree of overdiagnosis and overtreatment of otherwise clinically

72 rsial in large part because of high rates of overdiagnosis and overtreatment of otherwise indolent tu

73 es, and lack of women's perspectives lead to overdiagnosis and overtreatment of prolonged labour

74 y of neuroimaging techniques also results in overdiagnosis and overtreatment of so-called silent stro

75 ging of prostate cancer that has resulted in overdiagnosis and overtreatment of the disease.

76 aggressive PCa is urgently needed to reduce overdiagnosis and overtreatment of this common disease.

77 initiation for such patients while avoiding overdiagnosis and overtreatment of those with slow-growi

78 sesses physicians' recommendations regarding overdiagnosis and overtreatment of thyroid nodules and l

79 Diagnostic stewardship can decrease overdiagnosis and overtreatment, but optimal implementat

80 l benefit but substantial potential risk for overdiagnosis and overtreatment.

81 90s, and DCIS is viewed as a major driver of overdiagnosis and overtreatment.

82 ever, it also has potential harms, including overdiagnosis and overtreatment.

83 ificity and predictive value, which leads to overdiagnosis and overtreatment.

84 strategies to optimize TUS use and mitigate overdiagnosis and overtreatment.

85 or active surveillance and reduce prevalent overdiagnosis and overtreatment.

86 functional adverse effects, and the risk of overdiagnosis and overtreatment.

87 creasing diagnosis has led to concerns about overdiagnosis and overtreatment.

88 an also be detected by screening, leading to overdiagnosis and overtreatment.

89 rostate and thyroid cancers; the evidence of overdiagnosis and overtreatment; and provide overviews o

90 probability of disease likely contribute to overdiagnosis and overuse.

91 ancer natural history, including the role of overdiagnosis and race differences in tumor characterist

92 ormula industry, aims to reduce milk allergy overdiagnosis and support carers of children with suspec

93 egies to address the public-health issues of overdiagnosis and the consequent overtreatment of thyroi

94 creening foes, such as false-positive tests, overdiagnosis and the negative psychological impact of s

95 NAATs for the diagnosis of CDI, by reducing overdiagnosis and thereby increasing clinical specificit

96 hich harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit

97 nate screening for hypothyroidism has led to overdiagnosis and treatment initiation at lower serum le

98 agnostic inaccuracy that contributes to both overdiagnosis and underdiagnosis of prostate cancer.

99 diagnostic tests continues to result in both overdiagnosis and underdiagnosis of vulvovaginal candido

100 ough common, VWD is at risk of misdiagnosis, overdiagnosis and underdiagnosis owing to several factor

101 ith clinical and secondary findings to avoid overdiagnosis and unnecessary appendicectomies.

102 emains controversial due to the high rate of overdiagnosis and unnecessary prostate biopsies, despite

103 Volume-doubling time can only indicate overdiagnosis and was estimated for new cancer from 1 me

104 ursors to clinical attention, which leads to overdiagnosis and, if unrecognised, possible overtreatme

105 of disease severity, suggesting that reduced overdiagnosis and/or reduced misdiagnosis may be an expl

106 hat does not progress to EA over a lifetime (overdiagnosis) and missed BE that rapidly progresses to

107 ms (false-positive recalls, benign biopsies, overdiagnosis), and number of mammograms per 1000 women.

108 false-positive results, benign biopsies, and overdiagnosis); and ratios of harms (or use) and benefit

109 Harms included radiation exposure, overdiagnosis, and a high rate of false-positive finding

110 ubling of lung cancer incidence, no apparent overdiagnosis, and a more favorable stage shift.

111 rostate cancer, quality-adjusted life-years, overdiagnosis, and biopsies) and cost-effectiveness (net

112 ough endotyping, may help to avoid under- or overdiagnosis, and may provide the possibility to approa

113 y of care but worry about increased anxiety, overdiagnosis, and more frequent surveillance.

114 missing a case of true disease, overtesting, overdiagnosis, and overtreatment have become common.

115 iety associated with false-positive results, overdiagnosis, and previous knowledge of cancer or livin

116 eviating the increasing workload, preventing overdiagnosis, and reducing the dependence on experience

117 Urinary tract infections are prone to overdiagnosis, and reflex urine culture protocols offer

118 eening, including false-positive results and overdiagnosis, and the costs of screening can be substan

119 on of the CKD burden in an aging population, overdiagnosis, and unnecessary interventions in many eld

120 of harm related to false positive findings, overdiagnosis, and unnecessary invasive testing is real.

121 Although overdiagnosis, anxiety, pain, and radiation exposure may

122 Cow's milk allergy (CMA) overdiagnosis appears to be increasing and is associated

123 Overdiagnosis appears to be relatively greater in Americ

124 High rates of overdiagnosis are a critical barrier to organized prosta

125 Epidemiologic studies of overdiagnosis are challenged by unclear definitions and

126 Underdiagnosis and overdiagnosis are common and due to the lack of standard

127 First, different ways to define and measure overdiagnosis are considered.

128 urther characterize the burden and trends of overdiagnosis as well as identify strategies to reduce o

129 There is uncertainty about the magnitude of overdiagnosis associated with different screening strate

130 iomarkers have the potential to minimise the overdiagnosis associated with PSA screening.

131 The estimated rate of overdiagnosis attributable to the program was 18% to 25%

132 adherence to screening, degree of length or overdiagnosis bias in the first year of screening, quali

133 ning programs such as lead time, length, and overdiagnosis bias.

134 ributable to lead-time bias, length bias, or overdiagnosis bias.

135 roach that goes further to focus not only on overdiagnosis but also on the broader problem of diagnos

136 This reduces LC-MGUS overdiagnosis by 91% (10.7% vs 0.97%).

137 ced the number of both lifetime biopsies and overdiagnosis by approximately 50% and had a high probab

138 with elevated PSA levels reduced the risk of overdiagnosis by half at the cost of delaying detection

139 help improve diagnostic accuracy and reduce overdiagnosis by identifying the most likely diagnosis b

140 Guidelines may promote milk allergy overdiagnosis by labelling normal infant symptoms as pos

141 ):1812-1817) seeks to clarify the concept of overdiagnosis by screening.

142 Overdiagnosis can have serious negative consequences inc

143 Overdiagnosis can occur for several different reasons in

144 proaches were used to estimate the amount of overdiagnosis: comparing the incidence of advanced and n

145 -positive mammograms, benign biopsy results, overdiagnosis, cost-effectiveness, and ratio of false-po

146 the size of detected tumors and to estimate overdiagnosis (detection of tumors that would not become

147 These stem primarily from a backlash against overdiagnosis due to prostate specific antigen-based scr

148 underdiagnosis (due to under-reporting) and overdiagnosis (due to an overuse of the term 'allergy')

149 This will make overdiagnosis easier to define and measure, and eventual

150 Overdiagnosis, especially in women, may be a substantial

151 Despite there still being uncertainty about overdiagnosis estimate, this meta-analysis suggested tha

152 ond, contextual features and how they affect overdiagnosis estimates are examined.

153 Overdiagnosis estimates varied greatly (0%-67% chance th

154 In recognition of the weaknesses of overdiagnosis estimation methods based on excess inciden

155 k melanoma is unlikely to be attributable to overdiagnosis given the stability of thin melanoma rates

156 pressed concerns about screening-associated "overdiagnosis." Given this dilemma, the critically think

157 ensive evaluation of evidence for or against overdiagnosis has ever been undertaken and is urgently n

158 Concerns about breast cancer overdiagnosis have increased the need to understand how

159 in approximately 200/1000 women screened and overdiagnosis (ie, finding breast cancer that would not

160 Estimates of the frequency of overdiagnosis in breast and prostate cancer screening va

161 sed men in a screened population, represents overdiagnosis in most cases.

162 provider concentration, suggesting possible overdiagnosis in some areas and/or underdiagnosis in oth

163 sis as well as identify strategies to reduce overdiagnosis in the future.

164 ld decrease heparin-induced thrombocytopenia overdiagnosis in the ICU setting.

165 in small infants and children can help avoid overdiagnosis in this group and can obviate the need for

166 idence and mortality and better characterize overdiagnosis in white Americans.

167 Cow's milk allergy (CMA) overdiagnosis in young children appears to be increasing

168 agnosed in women offered screening represent overdiagnosis (incidence increase of 48.3%).

169 o unnecessary tests and invasive procedures, overdiagnosis, incidental findings, and increases in dis

170 o unnecessary tests and invasive procedures, overdiagnosis, incidental findings, increases in distres

171 Results: Screening benefits and overdiagnosis increase with breast density and RR.

172 ional mortality reduction in all models, but overdiagnosis increased most substantially at older ages

173 Agreement vs disagreement that overdiagnosis is a public health issue for atypical nevi

174 hologists, 68% (95% CI, 59%-76%) agreed that overdiagnosis is a public health issue for atypical nevi

175 Overdiagnosis is common and has been reported for severa

176 CMA overdiagnosis is common in early infancy.

177 Overdiagnosis is common with breast and prostate cancer

178 Overdiagnosis is eliminated because resection was the on

179 most misdiagnosed neurological diseases, and overdiagnosis is especially common.

180 Cancer overdiagnosis is frequently estimated using the excess i

181 The quality of the evidence for overdiagnosis is not sufficient to estimate a lifetime r

182 These trends suggest overdiagnosis is occurring.

183 Although overdiagnosis is often suggested, no comprehensive evalu

184 The risk of overdiagnosis is partly mitigated, albeit not eliminated

185 t cancer that will never become symptomatic (overdiagnosis), leading to overtreatment.

186 thyroid ultrasonography (TUS) contributes to overdiagnosis, leading to unnecessary biopsies, procedur

187 ding diagnostic criteria is vital to prevent overdiagnosis, limit unnecessary elimination diets and p

188 Etymologically, overdiagnosis means too much diagnosis and stems from th

189 , extensive comorbidities, underdiagnosis or overdiagnosis, multifaceted interactions with genetics a

190 ions of practicing dermatopathologists about overdiagnosis nor possible associations between percepti

191 s of localized neuroblastoma in infants, the overdiagnosis observed in neuroblastoma screening studie

192 Obligate overdiagnosis occurs in 9% of DCIS and approximately 7%

193 Although some overdiagnosis occurs in mainland Europe, our data sugges

194 rostate cancer death to 2.15%, with risk for overdiagnosis of 3.3%.

195 In high-income countries, overdiagnosis of allergy has become recognised as an iss

196 Precise quantification of overdiagnosis of breast cancer (defined as the percentag

197 st cancer during the patient's lifetime, and overdiagnosis of breast cancer is a cause for concern.

198 r detection will improve outcomes or lead to overdiagnosis of breast cancer.

199 aphy screening did not result in significant overdiagnosis of breast cancer.

200 del, as a diagnostic adjunct that may reduce overdiagnosis of cellulitis.

201 ey are imprecise, potentially leading to the overdiagnosis of chronic kidney disease.

202 ibution of normal symptoms and contribute to overdiagnosis of CMA.

203 We observed marked overdiagnosis of COPD: 22.2% of patients with a diagnosi

204 negligible contribution of 0.15% to obligate overdiagnosis of DCIS and a contribution of less than 0.

205 tanding of this issue may be associated with overdiagnosis of DTCs.

206 Recent studies reveal a high occurrence of overdiagnosis of heparin-induced thrombocytopenia in sur

207 Overdiagnosis of heparin-induced thrombocytopenia remain

208 Despite evidence of overdiagnosis of in situ and invasive melanoma, neither

209 n patients and emerging strategies to reduce overdiagnosis of indolent cancers through an understandi

210 ue to the risk of false-positive results and overdiagnosis of indolent disease.

211 y harms from unnecessary prostate biopsy and overdiagnosis of indolent disease.

212 n the hospital setting, leading to potential overdiagnosis of infection when single-step nucleic acid

213 ded random systematic techniques have led to overdiagnosis of insignificant cancer and underdiagnosis

214 eigh the risks of false-positive results and overdiagnosis of insignificant prostate cancer, and it i

215 a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high

216 Higher SES was associated with overdiagnosis of low-risk PC and, conversely, lower risk

217 tate cancer mortality but also a concomitant overdiagnosis of low-risk tumors.

218 graphic screening programs may contribute to overdiagnosis of LQTS.

219 diagnostic miscues underlying the continued overdiagnosis of LQTS.

220 Although overdiagnosis of Lyme disease appears to be the more fre

221 Overdiagnosis of MDR TB may result in treatment with sec

222 The overdiagnosis of melanoma in situ (MIS) is well document

223 nd in this cohort study suggest considerable overdiagnosis of melanoma occurring among White patients

224 There is significant overdiagnosis of milk allergy in young children in some

225 cence (n = 1) was present but resulted in an overdiagnosis of mucosal abnormalities when anastomoses

226 t some negative NSAID challenge tests and an overdiagnosis of NSAIDH occur in patients with food-depe

227 Common reasons for overdiagnosis of OCD by the lay interviewers were inappr

228 Most patients (93%, 98 of 105) with RCI overdiagnosis of PD remained in the clinical trial for o

229 y decrease overuse of imaging procedures and overdiagnosis of PE.

230 fering, pointing out the underlying issue in overdiagnosis of prognostic uncertainty.

231 f magnetic resonance imaging (MRI) mitigates overdiagnosis of prostate cancer while improving the det

232 anced lung disease and leads to considerable overdiagnosis of pulmonary hypertension.

233 Choice of an inappropriate comparison group, overdiagnosis of salpingitis in IUD users, and inability

234 ne potential limitation of LDCT screening is overdiagnosis of slow growing and indolent cancers.

235 e increase in incidence can be attributed to overdiagnosis of small and indolent papillary thyroid ca

236 limitations of this study are the potential overdiagnosis of uncomplicated malaria by rapid diagnost

237 Overdiagnosis of urinary tract infections (UTIs) and unn

238 py for UTI without urine culture testing and overdiagnosis of UTI were common and associated with unn

239 As a result, there is an overdiagnosis of well-known causes, such as essential tr

240 mplications for diagnosing otitis media, the overdiagnosis of which is a primary factor in increased

241 ed and mortality reduction) and harms (e.g., overdiagnosis) of risk-based screening strategies using

242 populations to overdiagnosis, the effects of overdiagnosis on patients and emerging strategies to red

243 on of these indolent cancer cells has led to overdiagnosis, one of the major problems of contemporary

244 It is unclear whether this represents overdiagnosis or a true increase in incidence.

245 xist, there is little evidence of widespread overdiagnosis or misdiagnosis of ADHD or of widespread o

246 ms in 144 (14.7%), with 60 (6.1%) mentioning overdiagnosis or overuse.

247 failed to mention important harms, including overdiagnosis or overuse.

248 scuss medical tests that carry potential for overdiagnosis or overuse.

249 nd harms resulting from screening (including overdiagnosis) or treatment of thyroid cancer.

250 rimary care records, such as underdiagnosis, overdiagnosis, or ascertainment bias of chronic conditio

251 Pharmaceutical marketing can lead to overdiagnosis, overtreatment, and overuse of medications

252 e morbidity; mortality; and harms, including overdiagnosis, overtreatment, diagnostic procedure-relat

253 er groups showed mixed changes suggestive of overdiagnosis plus changes in underlying disease risk (d

254 ts (aged 18 years) with ADHD that focused on overdiagnosis plus studies that could be mapped to 1 or

255 commends that authors of studies quantifying overdiagnosis provide information about these features.

256 0.94 to 1.05); and a significant increase of overdiagnosis rate (NS, 38%; 95% CI, 14 to 63).

257 u (DCIS) lesions were overdiagnosed in 2010 (overdiagnosis rate of 24.4% [including DCIS] and 14.7% [

258 80 cases of DCIS were overdiagnosed in 2010 (overdiagnosis rate of 48.3% [including DCIS] and 38.6% [

259 ing at age 40 years) adds little to obligate overdiagnosis rates (0.15% for DCIS and less than 0.1% f

260 Type 1 overdiagnosis rates among screened women in the United S

261 Results Obligate overdiagnosis rates depend strongly on the age at which

262 ls are used to estimate obligate (or type 1) overdiagnosis rates for DCIS, invasive breast cancer, an

263 ncidence by age, are used to estimate type 1 overdiagnosis rates for the U.S. screening population.

264 Conclusion Type 1 overdiagnosis rates increase rapidly with age at screeni

265 ine studies using different methods reported overdiagnosis rates of 0% to 54%; rates from randomized

266 ntribution of less than 0.1% to the obligate overdiagnosis rates of invasive breast cancer and all br

267 Resulting age-dependent overdiagnosis rates, along with screen-detected breast c

268 Purpose To determine obligate overdiagnosis rates, defined as the percentage of women

269 n mortality but also led to higher costs and overdiagnosis rates.

270 Overdiagnosis refers to detection of disease that would

271 ay be due, in part, to additional lead time, overdiagnosis related to PSA testing, grade migration, o

272 Asthma underdiagnosis and overdiagnosis remain significant problems for healthcare

273 However, the extent to which overdiagnosis represents a true problem relates to the c

274 .97; P = .001), and correct understanding of overdiagnosis (RR, 0.84; 95% CI, 0.79-0.90; P < .001).

275 cle concludes with questions that readers of overdiagnosis studies can use to evaluate the validity a

276 This article identifies features of overdiagnosis studies that influence results and shows t

277 automatically permits unbiased estimation of overdiagnosis; sufficient follow-up and appropriate anal

278 ning in general and high-risk populations to overdiagnosis, the effects of overdiagnosis on patients

279 These findings suggest that overdiagnosis-the identification, through screening, of

280 ancer death (2.23%) but reduces the risk for overdiagnosis to 2.3%.

281 could disproportionately contribute to MCAS overdiagnosis, to the exclusion of more appropriate diag

282 r monitoring in Barrett's esophagus to avoid overdiagnosis/treatment highlights an important PCA them

283 Estimates of overdiagnosis vary from 1% to 10%.

284 The main cause of LQTS misdiagnosis or overdiagnosis was a prolonged QTc interval secondary to

285 Overdiagnosis was calculated as the difference between o

286 The percentage of overdiagnosis was calculated by accounting for the expec

287 CMA overdiagnosis was common: 16.1% had parent-reported cow'

288 CMA overdiagnosis was defined in three separate ways: parent

289 NAAT was 97.4% and 89.0%, respectively, and overdiagnosis was more than three times more common in N

290 To avoid overdiagnosis, we propose a new kappa/lambda ratio refer

291 ngly, in order to grasp, measure, and handle overdiagnosis, we should revive medicine's original goal

292 incidence, mortality from breast cancer, and overdiagnosis were compared using a time-dependent Cox p

293 Risk factors for CMA overdiagnosis were high practice-based low-allergy formu

294 Studies of overdiagnosis were highly heterogeneous, and estimates v

295 Estimates of overdiagnosis were no different from CBE for risk-based

296 On the other hand, there could be a NSAIDH overdiagnosis when anaphylaxis is the clinical manifesta

297 opsy criteria has resulted in a high rate of overdiagnosis, which constitutes one major obstacle to i

298 ould adopt risk-based approaches to minimize overdiagnosis while maintaining clinical benefits.

299 ow-grade DCIS lesions-indicative of possible overdiagnosis-with digital breast cancer screening.

300 es of deaths from breast cancer coupled with overdiagnosis within screening programmes have prompted